TEL AVIV, Israel, Aug. 04, 2023 (GLOBE NEWSWIRE) -- ImPact Biotech, the IMmune Photo Activated Cancer Treatment (IMPACT) specialist announces the U.S. Food and Drug Administration cleared ImPact’s ...
OXFORD, United Kingdom, June 22, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics ...
Barinthus Biotherapeutics plc has announced its strategic transformation focusing on immunology and inflammatory diseases, highlighting its promising immunotherapy VTP-1000 for celiac disease, which ...
Preliminary phase 3 trial data indicate padeliporfin vascular targeted photodynamic therapy has favorable efficacy and acceptable safety for low-grade UTUC. The use of padeliporfin vascular targeted ...
Padeliporfin VTP has demonstrated safety and efficacy for upper tract urothelial carcinoma treatment in a phase 1 study. Padeliporfin VTP is a combination product of a drug, padeliporfin administered ...
Investigational immunotherapy candidate, VTP-1000, seeks to address significant unmet need in people with celiac disease. An estimated one in 100 people globally suffer from celiac disease, for which ...
Phase 1/2 randomized, open-label, multicenter, Simon two-stage study of pelareorep combined with modified FOLFIRINOX +/- atezolizumab in patients with metastatic pancreatic ductal adenocarcinoma. This ...
Kinase gene expression profiling of metastatic tumor tissue to prioritize therapeutic targets in clear cell renal cell carcinoma. This is an ASCO Meeting Abstract from the 2015 Genitourinary Cancers ...
Positive Top-Line Results Achieved From Two Phase 1 Clinical Trials of BACE Inhibitor BI1181181/VTP-37948 in Alzheimer's Disease BI1181181/VTP-37948 Demonstrated Greater Than 80% Reduction of an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results